Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN2 + valganciclovir
- Development stage
- Phase 1
- Lead developer
- GenVivo
- Modality
- Gene Therapies, Small Molecules
- Administration
- Oral, Intratumoral
01
Overview
GEN2 + valganciclovir is a combination therapy being investigated for cancer treatment. GEN2 is a replication-incompetent gene transfer vector containing an mRNA genome that encodes an optimized prodrug activated enzyme (enhanced mutant herpes simplex thymidine kinase or HSV-eTK) and an immunostimulatory cytokine (GM-CSF). When administered with the oral prodrug valganciclovir (VGCV), HSV-eTK triggers tumor cell killing by releasing the patient's full complement of unique tumor antigens, including neoantigens, to directly stimulate immune activation. This process is facilitated and augmented by the locally secreted immunostimulatory cytokine. GEN2 is designed to be off-the-shelf without requiring tumor biopsies or genomic sequencing to generate personalized neoantigens.
- Other names
- GEN2 gene therapyGEN-2 gene therapyGEN 2 gene therapy
02
Targets
TK2 (Thymidine kinase 2)
Beyond the preview
Go deeper on GEN2 + valganciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN2 + valganciclovir.